计算溶液所需的质量、体积或浓度。
DCZ0415
有货
为什么选择此级别
Moligand™ 级 ，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients
In Vitro
DCZ0415 (10, 20 μM; 72 hours) shows a significant decrease in colony formation, indicating it inhibits cell proliferation. DCZ0415 (1.25-40 μM; 72 hours) induces a significant dose-dependent decrease of viability in\nMM cells. DCZ0415 (10, 20 μM; 24-72 hours) shows a dose-dependent relationship between DCZ0415 treatment and apoptotic cell death. DCZ0415 (10, 20 μM; 24 hours) induces a significant accumulation in G0/G1 MM cells. DCZ0415 (10 μM; 48 hours) decreases the protein levels of phosphorylated (p)-iκBα and phosphorylated (p)-NF-κB in MM cells. DCZ0415 has IC 50 s of 1.0–10 μM in CalcuSyn in MM cell lines. DCZ0415 exerts cytotoxic effects by inhibiting DNA 288 synthesis in MM cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: Multiple myeloma (MM) cells Concentration: 10, 20 μM Incubation Time: 72 hours Result: Showed a significant decrease in colony formation, indicating it inhibits cell proliferation. Cell Viability AssayCell Line: MM cells Concentration: 1.25, 2.5, 5, 10, 20, 40 μM Incubation Time: 72 hours Result: Induced a significant dose-dependent decrease of viability. Apoptosis AnalysisCell Line: MM cells Concentration: 10, 20 μM Incubation Time: 24, 48, 72 hours Result: Showed a dose-dependent relationship between DCZ0415 treatment and apoptotic cell death. Cell Cycle AnalysisCell Line: MM cells Concentration: 10 and 20 μM Incubation Time: 24 hours Result: Induced a significant accumulation in G0/G1 MM cells. Western Blot AnalysisCell Line: MM cells Concentration: 10 μM Incubation Time: 48 hours Result: Decreased the protein levels of phosphorylated (p)-iκBα and phosphorylated (p)-NF-κB in MM cells.
In Vivo
DCZ0415 (ip; 50 mg/kg/day for 14 days) significantly reduces the growth of MM cells-induced tumors in immune-deficient mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Nude mice (6-weeks-old) with H929 775 cells Dosage: 50 mg/kg Administration: Intraperitoneal injection; every day for 14 days Result: Significantly reduced the growth of MM cells-induced tumors.
IC50& Target:NF-κB
规格
规格或纯度
Moligand™,10mM in DMSO
英文名称
DCZ0415
生化机理
DCZ0415是一种强效的TRIP13抑制剂，它能损害非同源末端连接修复并抑制NF-κB的活性。DCZ0415 可在体外、体内以及抗药性骨髓瘤患者的原代细胞中诱导抗骨髓瘤活性。
储存条件
-80℃储存
运输条件
特低温运输
名称和识别符
技术文档
高级数据
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）